Glutamatergic dysfunction in Schizophrenia

AO Kruse, JR Bustillo - Translational Psychiatry, 2022 - nature.com
The NMDA-R hypofunction model of schizophrenia started with the clinical observation of
the precipitation of psychotic symptoms in patients with schizophrenia exposed to PCP or …

Treating negative symptoms in schizophrenia: an update

G Remington, G Foussias, G Fervaha, O Agid… - … treatment options in …, 2016 - Springer
Opinion Statement Interest in the negative symptoms of schizophrenia has increased rapidly
over the last several decades, paralleling a growing interest in functional, in addition to …

Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation

G Wolf, S Singh, K Blakolmer, L Lerer, T Lifschytz… - Molecular …, 2023 - nature.com
Schizophrenia is a widespread psychiatric disorder that affects 0.5–1.0% of the world's
population and induces significant, long-term disability that exacts high personal and …

Treatment for negative symptoms in schizophrenia: a comprehensive review

SRT Veerman, PFJ Schulte, L De Haan - Drugs, 2017 - Springer
Negative symptoms (such as amotivation and diminished expression) associated with
schizophrenia are a major health concern. Adequate treatment would mean important …

N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo …

M Farokhnia, A Azarkolah, F Adinehfar… - Clinical …, 2013 - journals.lww.com
Objectives Despite the burden of negative symptoms on quality of life in schizophrenic
patients, no completely effective treatment has been developed to address such symptoms …

Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial

Z Sepehrmanesh, M Heidary, N Akasheh… - Progress in Neuro …, 2018 - Elsevier
Background Schizophrenia is one of the most disabling psychiatric syndromes with the
prevalence of 1% in the general population. Despite availability of various antipsychotics …

The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review

RR Girgis, AW Zoghbi, DC Javitt… - Journal of psychiatric …, 2019 - Elsevier
Since the discovery of chlorpromazine in the 1950's, antipsychotic drugs have been the
cornerstone of treatment of schizophrenia, and all attenuate dopamine transmission at the …

Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic

T Lencz, AK Malhotra - Molecular psychiatry, 2015 - nature.com
Abstract The Psychiatric Genomics Consortium–Schizophrenia Workgroup (PGC–SCZ) has
recently published a genomewide association study (GWAS) identifying> 100 genetic loci …

Memantine in neurological disorders–schizophrenia and depression

K Czarnecka, J Chuchmacz, P Wójtowicz… - Journal of Molecular …, 2021 - Springer
Memantine is used in Alzheimer's disease treatment as a non-competitive modern-affinity
strong voltage-dependent N-methyl-D-aspartate receptor antagonist. The fundamental role …

Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study

MR Khodaie-Ardakani, O Mirshafiee, M Farokhnia… - Psychiatry …, 2014 - Elsevier
The objective of this study was to assess the efficacy and tolerability of minocycline add-on
to risperidone in treatment of negative symptoms of patients with chronic schizophrenia. In a …